Background
Pharmacist-led medication assessment programs are available as publicly funded health services in 8 of the 10 Canadian provinces. 1 Although the programs vary with respect to some details such as patient eligibility, they are all funded by provincial drug plans that have historically only paid for dispensing. Medication assessment programs aim to update medication lists, provide education and ensure rational and safe drug therapy; however, the primary purpose is not to reduce medication costs. 1 Nevertheless,
given that funding for these Canadian programs comes from provincial drug plans, it would be useful to know the impact of medication assessments on medication costs. There is significant research published regarding pharmacist-led medication assessments. Studies have found that the service can improve quality of life, medication appropriateness, patient knowledge, chronic disease management and patient satisfaction. [2] [3] [4] [5] [6] [7] Unfortunately, little is known about the impact of medication assessments on medication costs, particularly in the Canadian health system. Most studies were published over 15 years ago and many were performed within interprofessional team settings located outside of Canada, making it difficult to determine if the interventions studied are reflective of contemporary Canadian primary care pharmacist practice. 3, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] For example, in 1995, Jameson et al. 8 study found a reduction in number of medications (by 1.7 per patient) and annual savings of $86 per patient, while the second study found no differences. None of these studies included a description of the pharmacist service that was detailed enough to compare it with contemporary medication assessment programs. One Canadian randomized controlled trial was identified that measured medication costs, which was published in 2003 before publicly funded medication assessment programs were launched in Canada. 19 This study included 889
elderly patients who were taking 5 or more medications and who were recruited from 24 interprofessional family medicine clinics in Ontario. The intervention group received a medication assessment from pharmacists who had postgraduate degrees and worked as consultants in the clinics. Although 2.5 recommendations were made per patient, 72% of which were accepted by physicians, medication costs did not change. 19 A second Canadian study, which retrospectively analyzed drug plan billing data in British Columbia, measured trends in drug utilization in patients who received a medication assessment from a community pharmacist. 16 The study found small increases in the number of prescriptions dispensed and in medication costs RESEARCH BRIEF over time, but due to the observational nature of the data, causality could not be attributed to the medication assessments. Considering the expenditures currently being made by Canadian provincial drug plans on pharmacist-led medication assessment programs, it is surprising that so little is known about the impact of these programs on medication costs. In the 2016-17 fiscal year, the province of Saskatchewan, with a population of just over 1 million, spent $776,653 on its program. 23 The aim of this study was to measure the impact on medication costs of medication assessments delivered at a single community-based pharmacist practice in Saskatchewan.
Methods
This study was a retrospective chart audit of patients who attended the Medication Assessment Centre (MAC) in Saskatoon, Saskatchewan. The primary outcome was the change in overall medication costs before and after the medication assessments. The secondary outcomes were change in prescription medication costs, change in nonprescription medication costs and change in overall medication count (i.e., number of different medications taken by each patient).
The MAC is a nondispensing, pharmacistrun, patient care clinic that is located oncampus at the University of Saskatchewan. The MAC offers medication assessments that follow the policies and procedures of the Saskatchewan Medication Assessment Program (SMAP), which is the publicly funded medication assessment program in Saskatchewan. Approximately 53% of MAC patients are referred by family physicians, 34% self-refer and 13% are referred by other health professionals. 24 Most medication assessments provided under SMAP occur within community pharmacies. Although the MAC is not a community pharmacy, it is similar in that the pharmacist is not physically co-located with other health professionals and communicates with family physicians primarily via facsimile. Medication assessments at the MAC are provided by a pharmacist with a Bachelor of Pharmacy Degree (BSP) and a 1-year hospital residency (ACPR), but with no formal additional training in the provision of medication assessments. The MAC pharmacist is not responsible for additional duties that are common in community pharmacy settings, such as dispensing, vaccinations or patient self-care requests.
The medication assessments provided at the MAC and within community pharmacies in Saskatchewan require that the pharmacist meet with patients to 1) create a medication list, 2) educate patients about their medications and 3) ensure regimens are appropriate, effective and safe. This process includes a written report sent to the patient's family physician. To be eligible for reimbursement from the drug plan, patients in Saskatchewan must be 65 years or older and taking 1) 5 or more chronic medications, or 2) an anticoagulant, or 3) a medication listed in the Beers Criteria. 25 The MAC also provides assessments for patients who do not meet these criteria, since it is a teaching clinic that is partially funded by the University of Saskatchewan and does not rely on fee-for-service billings.
All patients who had an initial medication assessment at the MAC from May 2015 to February 2016 and who also had a follow-up appointment documented at least 3 months after their assessment were included in the study. The reason for requiring a follow-up appointment that occurred at least 3 months after the initial assessment was to ensure that enough time had passed and that data were available to assess the impact of the medication assessment.
Chart data of patients who met the inclusion criteria were extracted in June 2016. The medication lists (which included prescription and nonprescription drugs) compiled by the MAC pharmacist at initial appointments were compared with the medication lists compiled at the most recent follow-up appointment. If there were any differences between the medication lists (e.g., medication additions/discontinuations, dose adjustments), the charts were reviewed to determine if the changes were directly related to a recommendation made by the MAC pharmacist. Only changes that were a direct result of a MAC pharmacist recommendation were included in the medication cost analysis.
After excluding any medication changes that were not initiated by the MAC pharmacist, the cost of each patient's most recent medication list (i.e., postmedication assessment) was compared with the cost at the initial appointment (i.e., premedication assessment). Prescription drug costs were calculated using prices in the Saskatchewan Formulary, including the standard pharmacy markup and the maximum allowable dispensing fee of $11.40. Costs of prescription drugs not listed on the provincial formulary RESEARCH BRIEF were calculated using the wholesale costs from the community pharmacy on campus at the University of Saskatchewan. Nonprescription drug costs were calculated using retail prices from an online Canadian retailer (www.Well.ca).
The medication counts before and after the medication assessments were compared using a paired samples t test. The medication costs before and after the medication assessments were compared using the Wilcoxon signed-rank test, since it was determined that the data were not normally distributed, requiring a nonparametric test. Data analyses were completed using IBM SPSS Statistics software (version 25.0; SPSS, Inc., Chicago, IL). This protocol was approved by the University of Saskatchewan research ethics board.
Results
A total of 53 patients met the inclusion criteria. The mean age of study subjects was 65.4 years, 52.8% were male and patients were taking an average of 13.6 different medications at baseline. Overall monthly medication costs were reduced by $29.03 (or 7.8%) per patient, from a mean of $370.87 to $341.84 (p = 0.004) ( Table 1 ). The overall medication count was reduced from a mean of 13.6 medications per patient at baseline to 12.6 per patient (p < 0.001). The majority (74.4%) of the overall medication cost savings resulted from changes made to prescription drugs ( Table 1 ). The pharmacist recommendations that affected the medication cost and count differences are reported in Table 2 . Although the pharmacist recommended a variety of medication changes, "stopping drugs" or "decreasing doses" comprised 67.1% of all recommendations that affected medication cost and counts (Table 2) .
Discussion
This study found that medication assessments that follow the policies and procedures of the SMAP result in a reduction in monthly medication costs. This is an important finding because it provides evidence regarding the impact of a contemporary publicly funded medication assessment program. Considering that in Saskatchewan a pharmacist can bill the government $100 for this service ($60 for initial assessment and $20 for up to 2 follow-ups), a monthly saving of $29.03 is a financially important amount.
It is also significant that this study measured only changes that were a direct result of recommendations made by the pharmacist during the medication assessments, since this information was available in MAC patient charts. Previous studies that compared medication costs before and after a medication assessment were not able to identify changes made directly by the pharmacist and therefore may have unintentionally included changes initiated by other health professionals or patients themselves. This study was also able to separate the contributions of prescription and nonprescription drugs towards overall medication costs, while previous studies combined all medication costs. This is a useful distinction to make, particularly for informing policy decisions that are made by drug plans that pay for prescription drugs.
The only previously published data that were identified regarding the impact on medication costs of a current Canadian medication assessment program was an observational study from British Columbia that could not prove causality. 16 This study provides the first data, with evidence of causality, that the medication assessment program in Saskatchewan (SMAP) leads to statistically significant and economically important monthly cost savings of $29.03 per patient. This study has some limitations. It is not possible to determine if the savings identified in this study will be maintained indefinitely; however, the SMAP allows for annual reassessments, providing an opportunity for pharmacists to continue to follow these patients to maintain medication changes that were made. This study is also based on data from a single practice site that is located in a nondispensing patient care clinic, making it difficult to extrapolate the results to typical community pharmacy 
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settings. Although the medication assessments provided at the MAC followed the procedures of the SMAP, it is not known if pharmacists practising within a typical community pharmacy setting would have an impact that is similar to the results found in this study. However, the MAC is similar to community pharmacy settings in that the pharmacist works in isolation from other health professionals and communicates with family physicians mostly using written consultation notes. It is also important to note that this study only measured the impact of the medication assessments on medication costs and did not consider other health system costs, such as those resulting from undertreatment of chronic medical conditions or negative consequences of inappropriate use of medications.
Future research should determine if these results are consistent when medication assessments are performed across multiple different community pharmacies and in a larger sample of patients. It would also be valuable to measure the overall cost-effectiveness of the service, including the expenses required to provide the service and health system cost impacts beyond medications.
Conclusion
Pharmacist-led medication assessments performed according to the procedures outlined by the Saskatchewan Medication Assessment Program resulted in a significant reduction in the overall number of medications taken and overall monthly medication costs. ■ 
